EJNMMI Research

Papers
(The TQCC of EJNMMI Research is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Nanobody: a promising toolkit for molecular imaging and disease therapy76
Convolutional neural networks for improving image quality with noisy PET data47
Independent attenuation correction of whole body [18F]FDG-PET using a deep learning approach with Generative Adversarial Networks44
Use of static and dynamic [18F]-F-DOPA PET parameters for detecting patients with glioma recurrence or progression36
Intraindividual comparison of [68 Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis33
Hypoxia imaging and theranostic potential of [64Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms33
[99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center33
Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review33
Added value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy32
A DROP-IN beta probe for robot-assisted 68Ga-PSMA radioguided surgery: first ex vivo technology evaluation using prostate cancer specimens31
Predictive value of quantitative 18F-FDG-PET radiomics analysis in patients with head and neck squamous cell carcinoma28
Simultaneous in vivo PET/MRI using fluorine-18 labeled Fe3O4@Al(OH)3 nanoparticles: comparison of nanoparticle and nanoparticle-labeled stem cell distribution28
FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients27
PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer26
A three-stage, deep learning, ensemble approach for prognosis in patients with Parkinson’s disease26
Phantom and clinical evaluation of bone SPECT/CT image reconstruction with xSPECT algorithm26
Comparison of diagnostic sensitivity of [18F]fluoroestradiol and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of est25
Preclinical comparison of four [18F, natGa]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics25
Fluorescent image-guided surgery in breast cancer by intravenous application of a quenched fluorescence activity-based probe for cysteine cathepsins in a syngeneic mouse model24
Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study24
Preoperative prediction of pathological grade in pancreatic ductal adenocarcinoma based on 18F-FDG PET/CT radiomics24
Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours22
Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer22
Voxel-based comparison of [68Ga]Ga-RM2-PET/CT and [68Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer22
Diagnostic value of [18F]FDG PET/MRI for staging in patients with ovarian cancer22
Deep learning-based amyloid PET positivity classification model in the Alzheimer’s disease continuum by using 2-[18F]FDG PET21
Head and neck tumors angiogenesis imaging with 68Ga-NODAGA-RGD in comparison to 18F-FDG PET/CT: a pilot study21
Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study21
Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG19
Preliminary study of AI-assisted diagnosis using FDG-PET/CT for axillary lymph node metastasis in patients with breast cancer19
Impact of the Q.Clear reconstruction algorithm on the interpretation of PET/CT images in patients with lymphoma19
The pons as reference region for intensity normalization in semi-quantitative analysis of brain 18FDG PET: application to metabolic changes related to ageing in conventional and digital control databa18
Automated liver lesion detection in 68Ga DOTATATE PET/CT using a deep fully convolutional neural network18
Normal values for 18F-FDG uptake in organs and tissues measured by dynamic whole body multiparametric FDG PET in 126 patients18
[11C]PIB amyloid quantification: effect of reference region selection17
CERMEP-IDB-MRXFDG: a database of 37 normal adult human brain [18F]FDG PET, T1 and FLAIR MRI, and CT images available for research17
Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer17
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer17
The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.017
Detection of the sentinel lymph node with hybrid tracer (ICG-[99mTc]Tc-albumin nanocolloid) in intermediate- and high-risk endometrial cancer: a feasibility study16
Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients16
First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer16
Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer15
Repeatability of two semi-automatic artificial intelligence approaches for tumor segmentation in PET15
PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?15
External validation: a simulation study to compare cross-validation versus holdout or external testing to assess the performance of clinical prediction models using PET data from DLBCL patients15
Diagnostic value of PET/CT with 11C-methionine (MET) and 18F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification15
Disease activity and response to therapy monitored by [18F]FDG PET/CT using volume-based indices in IgG4-related disease15
Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study15
Imaging modalities for diagnosis and monitoring of cancer cachexia15
Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients15
The value of 18F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer15
A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer14
Mechanisms underlying the predictive power of high skeletal muscle uptake of FDG in amyotrophic lateral sclerosis14
[18F]-Fluciclovine PET discrimination of recurrent intracranial metastatic disease from radiation necrosis14
Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET14
Detection and therapy of neuroblastoma minimal residual disease using [64/67Cu]Cu-SARTATE in a preclinical model of hepatic metastases14
[18F]FEPPA PET imaging for monitoring CD68-positive microglia/macrophage neuroinflammation in nonhuman primates14
L-type amino acid transporter (LAT) 1 expression in 18F-FET-negative gliomas13
Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson’s disease13
Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study13
Benefits and harms of implementing [18F]FDG-PET/CT for diagnosing recurrent breast cancer: a prospective clinical study13
99mTc-labelled PSMA ligand for radio-guided surgery in nodal metastatic prostate cancer: proof of principle13
Imaging angiogenesis in atherosclerosis in large arteries with 68Ga-NODAGA-RGD PET/CT: relationship with clinical atherosclerotic cardiovascular disease13
Quantitative SPECT/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis13
There is a world beyond αvβ3-integrin: Multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8, αvβ3, and α5β1 by positron emission tomography13
Evaluation of camera-based freehand SPECT in preoperative sentinel lymph node mapping for melanoma patients13
First-in-human use of 11C-CPPC with positron emission tomography for imaging the macrophage colony-stimulating factor 1 receptor13
Combatting the effect of image reconstruction settings on lymphoma [18F]FDG PET metabolic tumor volume assessment using various segmentation methods13
A retrospective analysis of the diagnostic performance of 11C-choline PET/CT for detection of hyperfunctioning parathyroid glands after prior negative or discordant imaging in primary hyperparathyroid12
The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)12
Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)12
Sapap3 deletion causes dynamic synaptic density abnormalities: a longitudinal [11C]UCB-J PET study in a model of obsessive–compulsive disorder-like behaviour12
[18F]FDG uptake of bone marrow on PET/CT for predicting distant recurrence in breast cancer patients after surgical resection12
Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer12
Clinical implementation of PLANET® Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.012
[177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results12
Blocking of efflux transporters in rats improves translational validation of brain radioligands12
18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy12
Evaluation of image quality with four positron emitters and three preclinical PET/CT systems12
TSPO PET detects acute neuroinflammation but not diffuse chronically activated MHCII microglia in the rat12
High uptake of 68Ga-PSMA and 18F-DCFPyL in the peritumoral area of rat gliomas due to activated astrocytes12
FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: a prospective study with comparison to FDG-PET11
The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy11
Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study11
Risk factors for nonvisualization of the sentinel lymph node on lymphoscintigraphy in breast cancer patients11
PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy11
Lung shunt fraction calculation using 99mTc-MAA SPECT/CT imaging for 90Y microsphere selective internal radiation therapy of liver tumors11
Kinfitr — an open-source tool for reproducible PET modelling: validation and evaluation of test-retest reliability11
Extravasation of [177Lu]Lu-DOTATOC: case report and discussion11
Synthesis of a novel 89Zr-labeled HER2 affibody and its application study in tumor PET imaging11
Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL)11
Metabolic network as an objective biomarker in monitoring deep brain stimulation for Parkinson’s disease: a longitudinal study11
Yttrium-90 radioembolization as a possible new treatment for brain cancer: proof of concept and safety analysis in a canine model10
Correlations between baseline 18F-FDG PET tumour parameters and circulating DNA in diffuse large B cell lymphoma and Hodgkin lymphoma10
177Lu radiolabeling and preclinical theranostic study of 1C1m-Fc: an anti-TEM-1 scFv-Fc fusion protein in soft tissue sarcoma10
A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy10
Radiobiological and dosimetric assessment of DNA-intercalated 99mTc-complexes bearing acridine orange derivatives10
PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP10
Initial evaluation of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (FSPG) PET/CT imaging in patients with head and neck cancer, colorectal cancer, or non-Hodgkin lymphoma10
Evaluation of 18F-AlF-NOTA-octreotide for imaging neuroendocrine neoplasms: comparison with 68Ga-DOTATATE PET/CT10
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-100710
[68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study10
[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma10
Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision10
Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging10
A convolutional neural network for total tumor segmentation in [64Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms10
Fluorescence labeling of a NaV1.7-targeted peptide for near-infrared nerve visualization10
Tracking a TGF-β activator in vivo: sensitive PET imaging of αvβ8-integrin with the Ga-68-labeled cyclic RGD octapeptide trimer Ga-68-Triveoctin10
Magnetic nanoparticles in theranostics of malignant melanoma9
Detection limit of 89Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI9
Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy9
Comparison of [18F]FDG PET/CT with magnetic resonance imaging for the assessment of human brown adipose tissue activity9
A dedicated paediatric [18F]FDG PET/CT dosage regimen9
A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using [18F]MK-62409
Dealing with PET radiometabolites9
Whole-body [18F]-FDG-PET/MRI for staging of pediatric non-Hodgkin lymphoma: first results from a single-center evaluation9
Value of 18F-FDG PET/CT-based radiomics model to distinguish the growth patterns of early invasive lung adenocarcinoma manifesting as ground-glass opacity nodules9
In vitro and pilot in vivo imaging of 18 kDa translocator protein (TSPO) in inflammatory vascular disease9
Sex correction improves the accuracy of clinical dopamine transporter imaging9
Day-to-day variability of [68Ga]Ga-PSMA-11 accumulation in primary prostate cancer: effects on tracer uptake and visual interpretation9
Conscious rat PET imaging with soft immobilization for quantitation of brain functions: comprehensive assessment of anesthesia effects on cerebral blood flow and metabolism9
In vitro proof of concept studies of radiotoxicity from Auger electron-emitter thallium-2019
Combined PET/CT with thoracic contrast-enhanced CT in assessment of primary cardiac tumors in adult patients9
0.047648906707764